You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 10,159,675


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,159,675
Title:Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione
Abstract: Provided herein are methods of treating, preventing and/or managing cancer, including lymphoma, which comprise administering to a patient 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a cyclic therapy regimen.
Inventor(s): Hagner; Patrick (Sparta, NJ), Gandhi; Anita (Bernardsville, NJ), Pourdehnad; Michael (San Francisco, CA)
Assignee: Celgene Corporation (Summit, NJ)
Application Number:15/367,117
Patent Claims:1. A method for treating, managing, and/or ameliorating lymphoma, while reducing an adverse effect associated with such treating, managing, and/or ameliorating, said method comprising administering to a patient in need thereof an effective amount of compound 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, which has the following structure: ##STR00004## or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, stereoisomer, tautomer or racemic mixture thereof, wherein the compound is administered to said subject in a cycling therapy, said cycling therapy comprising: an administration period of 5 days followed by a rest period of 2 days.

2. The method of claim 1, wherein the compound is a solvate of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione.

3. The method of claim 1, wherein the compound is a hydrate of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione.

4. The method of claim 1, wherein the compound is a pharmaceutically acceptable salt of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione.

5. The method of claim 1, wherein the compound is 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione.

6. The method of claim 1, wherein the adverse effect comprises neutropenia.

7. The method of claim 1, wherein the compound is administered orally.

8. The method of claim 1, wherein the compound is administered at a dose of about 1 mg to about 5 mg.

9. The method of claim 8, wherein the dose is about 3 mg or about 4mg.

10. The method of claim 8, wherein the dose is about 4 mg.

11. The method of claim 8, wherein the dose is about 3 mg.

12. The method of claim 1, wherein the cycling therapy is repeated 2 to 6times.

13. The method of claim 1, wherein the method further comprises co-administering a second therapeutic agent.

14. The method of claim 13, wherein said second therapeutic agent is selected from oblimersen, GM-CSF, G-CSF, SCF, EPO, rituximab, obinutuzumab, tositumomab,131I tositumomab, 90Y ibritumomab, 111I ibritumomab, ofatumumab, brentuximab vedotin, nelarabine, cyclophosphamide, chlorambucil, bendamustine, carmustine, ifosfamide, prednisone, dexamethasone, cisplatin, carboplatin, oxaliplatin, fludarabine, pentostatin, cladribine, cytarabine, gemcitabine, methotrexate, pralatrexate, vincristine, vinblastine sulfate, doxorubicin, mitoxantrone, etoposide, belinostat, bortezomib, denileukin diftitox, ibrutinib, idelalisib, intron A, recombinant interferon Alfa-2b, romidepsin, lenalidomide, mechlorethamine hydrochloride, plerixafor, vorinostat, and bleomycin, or a combination thereof.

15. The method of claim 1, wherein the lymphoma is non-Hodgkin lymphoma.

16. The method of claim 1, wherein the lymphoma is diffuse large B-cell lymphoma.

17. The method of claim 16, wherein the diffuse large B-cell lymphoma is activated B-cell type.

18. The method of claim 16, wherein the diffuse large B-cell lymphoma is germinal center B-cell type.

19. The method of claim 16, wherein the diffuse large B-cell lymphoma is of unclassified cell of origin.

20. The method of claim 16, wherein the diffuse large B-cell lymphoma is relapsed or refractory.

21. The method of claim 1, wherein the lymphoma is mantle cell lymphoma.

22. The method of claim 1, wherein the lymphoma is relapsed or refractory.

Details for Patent 10,159,675

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2035-12-02
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2035-12-02
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2035-12-02
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2035-12-02
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.